Health Technology Assessment: Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis
Key data
Project team
Cécile Grobet, Maxim Sharakin, Linda Vinci, Maria Carlander, Flurina Meier, Prof. Dr. Philipp Egli, Prof. Dr. Andreas Gerber-Grote, Prof. Dr. Simon Wieser
Project status
completed, 01/2020 - 10/2021
Institute/Centre
Winterthur Institute of Health Economics (WIG); School of Health Sciences; Institute of Enterprise Law (IUR)
Funding partner
Bundesamt für Gesundheit BAG / Sektion Health Technology Assessment (HTA)
Project budget
165'000 CHF
